Statistical analysis
The full analysis set consists of all enrolled patients who receive ≥ 1 dose of vibegron and have ≥ 1 postbaseline assessment and is used for the analysis of treatment satisfaction, QoL, HCRU, and treatment patterns. The safety analysis set consists of all enrolled patients who receive ≥ 1 dose of vibegron and is used for analysis of safety data. Patients are assigned to 1 of 2 cohorts based on previous OAB treatment exposure: Cohort A consists of patients with previous anticholinergic therapy, whereas cohort B consists of patients with previous mirabegron monotherapy or combination therapy with solifenacin. Summaries will be reported for each cohort separately and for the combined cohorts.Descriptive analyses will be performed to assess quantitative data collected to understand the characteristics of the cohorts studied. Interim analyses will be conducted after most patients have completed the 3- and 6-month questionnaires; the final analysis will be performed 12 months after the last patient is enrolled. Data will be analyzed using SAS